false 2024 Q1 0001631569 12/31 seven years, three months http://fasb.org/us-gaap/2023#OtherAssets http://fasb.org/us-gaap/2023#OtherAssets http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#InterestExpense http://fasb.org/us-gaap/2023#InterestExpense http://fasb.org/us-gaap/2023#InterestExpense http://fasb.org/us-gaap/2023#InterestExpense P3Y 33 33 33 http://fasb.org/us-gaap/2023#OtherAssets http://fasb.org/us-gaap/2023#OtherAssets http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilities 0001631569 2024-01-01 2024-03-31 0001631569 2024-04-24 xbrli:shares 0001631569 2024-03-31 iso4217:USD 0001631569 2023-12-31 iso4217:USD xbrli:shares 0001631569 2023-01-01 2023-03-31 0001631569 us-gaap:PreferredStockMember 2023-12-31 0001631569 us-gaap:CommonStockMember 2023-12-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2023-12-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001631569 chct:CumulativeDividendsMember 2023-12-31 0001631569 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2024-01-01 2024-03-31 0001631569 chct:CumulativeDividendsMember 2024-01-01 2024-03-31 0001631569 us-gaap:PreferredStockMember 2024-03-31 0001631569 us-gaap:CommonStockMember 2024-03-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2024-03-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001631569 chct:CumulativeDividendsMember 2024-03-31 0001631569 us-gaap:PreferredStockMember 2022-12-31 0001631569 us-gaap:CommonStockMember 2022-12-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2022-12-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001631569 chct:CumulativeDividendsMember 2022-12-31 0001631569 2022-12-31 0001631569 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2023-01-01 2023-03-31 0001631569 chct:CumulativeDividendsMember 2023-01-01 2023-03-31 0001631569 us-gaap:PreferredStockMember 2023-03-31 0001631569 us-gaap:CommonStockMember 2023-03-31 0001631569 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001631569 chct:CumulativeNetIncomeDeficitMember 2023-03-31 0001631569 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001631569 chct:CumulativeDividendsMember 2023-03-31 0001631569 2023-03-31 chct:real_estate_property chct:state utr:sqft xbrli:pure 0001631569 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-03-31 0001631569 chct:MedicalOfficeBuildingMember 2024-03-31 0001631569 chct:InpatientRehabilitationHospitalMember 2024-03-31 0001631569 chct:AcuteInpatientBehavioralMember 2024-03-31 0001631569 chct:SpecialtyCentersMember 2024-03-31 0001631569 chct:PhysicianClinicsMember 2024-03-31 0001631569 chct:SurgicalCentersandHospitalsMember 2024-03-31 0001631569 chct:BehavioralFacilitiesMember 2024-03-31 0001631569 chct:LongTermAcuteCareFacilityMember 2024-03-31 0001631569 stpr:TX 2024-03-31 0001631569 stpr:IL 2024-03-31 0001631569 stpr:OH 2024-03-31 0001631569 stpr:FL 2024-03-31 0001631569 stpr:PA 2024-03-31 0001631569 chct:OtherStatesMember 2024-03-31 0001631569 chct:LifePointHealthMember 2024-03-31 0001631569 chct:USHealthVestMember 2024-03-31 0001631569 chct:OtherTenantMember 2024-03-31 0001631569 chct:GenesisCareMember 2024-02-16 chct:lease 0001631569 chct:TenRealEstatePropertyMember 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member 2024-01-01 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:NewBedfordMAMember 2024-01-01 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:NewBedfordMAMember 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:ElktonMDMember 2024-01-01 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:ElktonMDMember 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:BemidjiMNMember 2024-01-01 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuringQ12024Member chct:BemidjiMNMember 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuring2024Member 2024-01-01 2024-03-31 0001631569 chct:AcquisitionsOfPropertiesDuring2024Member 2024-03-31 0001631569 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-03-31 0001631569 us-gaap:LandAndLandImprovementsMember us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-03-31 0001631569 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-03-31 0001631569 us-gaap:LeasesAcquiredInPlaceMember us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-03-31 0001631569 us-gaap:AboveMarketLeasesMember us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-03-31 0001631569 us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember 2024-01-01 2024-03-31 0001631569 us-gaap:LandMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-03-31 0001631569 us-gaap:LandMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-12-31 0001631569 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember chct:BuildingsImprovementsAndLeaseholdsMember 2024-03-31 0001631569 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember chct:BuildingsImprovementsAndLeaseholdsMember 2023-12-31 0001631569 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:RealEstateMember 2024-03-31 0001631569 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:RealEstateMember 2023-12-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:LineOfCreditMember 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A3TermLoanMember chct:TermLoanMember 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A3TermLoanMember chct:TermLoanMember 2023-12-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A4TermLoanMember chct:TermLoanMember 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A4TermLoanMember chct:TermLoanMember 2023-12-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A5TermLoanMember chct:TermLoanMember 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A5TermLoanMember chct:TermLoanMember 2023-12-31 0001631569 us-gaap:MortgagesMember 2024-03-31 0001631569 us-gaap:MortgagesMember 2023-12-31 0001631569 chct:TermLoanMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:LineOfCreditMember 2024-03-31 chct:option 0001631569 us-gaap:RevolvingCreditFacilityMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A3TermLoanMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A4TermLoanMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:CreditFacilityAccordionFeatureMember 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:ThirdAmendedAndRestatedCreditFacilityMember srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:BaseRateMember srt:MinimumMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:BaseRateMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:RevolvingCreditFacilityUnusedBorrowingCapacityRate1Member us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:RevolvingCreditFacilityUnusedBorrowingCapacityRate2Member us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 srt:MaximumMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 srt:MaximumMember chct:ThirdAmendedAndRestatedCreditFacilityMember chct:SimpleSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:BaseRateMember srt:MinimumMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 srt:MaximumMember chct:ThirdAmendedAndRestatedCreditFacilityMember us-gaap:BaseRateMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:TermLoanMember 2024-03-31 0001631569 us-gaap:MortgagesMember us-gaap:BuildingMember 2024-03-31 0001631569 chct:ThirdAmendedAndRestatedCreditFacilityMember chct:A5TermLoanMember chct:TermLoanMember 2024-01-01 2024-03-31 0001631569 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-03-29 chct:derivative_instrument 0001631569 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-03-31 0001631569 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-03-31 0001631569 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-03-31 0001631569 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-12-31 0001631569 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0001631569 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0001631569 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0001631569 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0001631569 2023-01-01 2023-12-31 0001631569 chct:AtTheMarketOfferingProgramMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001631569 chct:AtTheMarketOfferingProgramMember us-gaap:CommonStockMember 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2023-12-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2022-12-31 0001631569 chct:A2014IncentivePlanMember chct:RestrictedCommonStockStockinLieuofCompensationMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember chct:RestrictedCommonStockStockinLieuofCompensationMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember chct:RestrictedCommonStockStockAwardsMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember chct:RestrictedCommonStockStockAwardsMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2023-03-31 0001631569 us-gaap:RestrictedStockMember srt:ChiefExecutiveOfficerMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember 2024-01-02 0001631569 chct:A2014IncentivePlanMember 2024-01-01 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-02 2024-01-02 0001631569 srt:ExecutiveOfficerMember chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-02 2024-01-02 0001631569 srt:ExecutiveOfficerMember chct:AbsoluteTSRUnitsMember chct:A2014IncentivePlanMember 2024-01-02 2024-01-02 0001631569 chct:RelativeTSRUnitsMember srt:ExecutiveOfficerMember chct:A2014IncentivePlanMember 2024-01-02 2024-01-02 0001631569 srt:ExecutiveOfficerMember chct:A2014IncentivePlanMember chct:TimeBasedTSRUnitsMember 2024-01-02 2024-01-02 0001631569 chct:PerformanceBasedRestrictedStockUnitsMember chct:A2014IncentivePlanMember 2024-01-02 2024-01-02 0001631569 chct:PerformanceBasedRestrictedStockUnitsMember chct:A2014IncentivePlanMember 2024-01-02 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001631569 chct:AbsoluteTSRUnitsMember chct:A2014IncentivePlanMember 2024-01-01 2024-03-31 0001631569 chct:AbsoluteTSRUnitsMember chct:A2014IncentivePlanMember 2023-01-01 2023-03-31 0001631569 chct:RelativeTSRUnitsMember chct:A2014IncentivePlanMember 2024-01-01 2024-03-31 0001631569 chct:RelativeTSRUnitsMember chct:A2014IncentivePlanMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember chct:TimeBasedTSRUnitsMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember chct:TimeBasedTSRUnitsMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001631569 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RestrictedStockMember 2024-01-12 2024-01-12 0001631569 us-gaap:ShareBasedPaymentArrangementEmployeeMember srt:MinimumMember us-gaap:RestrictedStockMember 2024-01-12 2024-01-12 0001631569 srt:MaximumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RestrictedStockMember 2024-01-12 2024-01-12 0001631569 chct:A2014IncentivePlanMember chct:RestrictedCommonStockStockInLieuOfCompensationRestrictedPeriodMember 2024-01-01 2024-03-31 0001631569 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:RestrictedStockMember 2024-01-12 2024-01-12 0001631569 chct:A2024IncentivePlanMember 2024-03-04 0001631569 us-gaap:ShareBasedCompensationAwardTrancheOneMember chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001631569 us-gaap:ShareBasedCompensationAwardTrancheTwoMember chct:A2014IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001631569 chct:A2014IncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001631569 chct:NoteReceivable1Member us-gaap:NotesReceivableMember 2024-03-31 0001631569 chct:NoteReceivable1Member us-gaap:NotesReceivableMember 2023-12-31 0001631569 chct:NoteReceivable1Member chct:LongTermAcuteCareFacilityMember 2024-01-01 2024-03-31 chct:hospital 0001631569 chct:NoteReceivable1Member chct:InpatientRehabilitationHospitalMember 2024-01-01 2024-03-31 0001631569 chct:NoteReceivable1Member us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0001631569 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember chct:NoteReceivable3Member 2023-12-31 0001631569 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember chct:NoteReceivable3Member 2024-03-31 0001631569 chct:NoteReceivable2Member us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-03-31 0001631569 chct:NoteReceivable2Member us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-12-31 0001631569 chct:GeriatricBehavioralHospitalMember 2024-01-01 2024-03-31 0001631569 chct:NoteReceivable2Member us-gaap:UnfundedLoanCommitmentMember 2024-03-31 0001631569 us-gaap:UnfundedLoanCommitmentMember chct:NoteReceivable3Member 2024-03-31 0001631569 us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0001631569 us-gaap:NotesReceivableMember 2024-03-31 0001631569 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember chct:NoteReceivable4Member 2024-03-31 0001631569 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember chct:NoteReceivable4Member 2023-12-31 0001631569 chct:NoteReceivable4Member us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:NoteReceivable4Member 2024-01-01 2024-03-31 0001631569 us-gaap:RevolvingCreditFacilityMember chct:NoteReceivable4Member 2024-03-31 0001631569 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember chct:NoteReceivable1Member 2024-03-31 0001631569 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0001631569 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2024-03-31 0001631569 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001631569 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001631569 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:InterestRateSwapMember 2024-03-31 0001631569 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2024-03-31 0001631569 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:InterestRateSwapMember 2023-12-31 0001631569 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001631569 chct:TenantImprovementsAllowancesMember 2024-03-31 0001631569 chct:RedevelopmentProjectsMember 2024-01-01 2024-03-31 chct:project 0001631569 chct:RedevelopmentProjectsMember 2024-03-31 0001631569 chct:CapitalImprovementsMember 2024-03-31 0001631569 us-gaap:SubsequentEventMember 2024-04-25 2024-04-25 0001631569 chct:InpatientRehabilitationFacilityMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0001631569 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One) |  |
☒ |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024
OR
☐ |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-37401

Community Healthcare Trust Incorporated
(Exact Name of Registrant as Specified in Its Charter)

Maryland |  | 46-5212033
(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)

3326 Aspen Grove Drive
Suite 150
Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 771-3052
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:

| Title of each Class | Trading Symbol | Name of each exchange on which registered |
| Common stock, $0.01 par value per share | CHCT | New York Stock Exchange |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐ | Emerging-growth company | ☐ | Non-accelerated filer | ☐ | Smaller reporting company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The Registrant had 27,701,196 shares of Common Stock, $0.01 par value per share, outstanding as of April 24, 2024.
1

COMMUNITY HEALTHCARE TRUST INCORPORATED
FORM 10-Q
MARCH 31, 2024
TABLE OF CONTENTS

|  | Page
PART I.—FINANCIAL INFORMATION |
Item 1. | Financial Statements (Unaudited) | 3
| Condensed Consolidated Balance Sheets | 3
| Condensed Consolidated Statements Of Operations | 4
| Condensed Consolidated Statements of Comprehensive Income (Loss) | 5
| Condensed Consolidated Statements of Stockholders' Equity | 6
| Condensed Consolidated Statements of Cash Flows | 8
| Notes to Condensed Consolidated Financial Statements | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 34
Item 4. | Controls and Procedures | 34
PART II.—OTHER INFORMATION | 35
Item 1. | Legal Proceedings | 35
Item 1A. | Risk Factors | 35
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 35
Item 3. | Defaults Upon Senior Securities | 35
Item 4. | Mine Safety Disclosures | 35
Item 5. | Other Information | 35
Item 6. | Exhibits | 35
SIGNATURES | 38

2

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars and shares in thousands, except per share amounts)

| (Unaudited) |  |
| March 31, 2024 |  | December 31, 2023
ASSETS |  |  |
Real estate properties |  |  |
Land and land improvements | $ | 142,120 |  |  | $ | 136,532 |
Buildings, improvements, and lease intangibles | 948,253 |  |  | 913,416 |
Personal property | 317 |  |  | 299 |
Total real estate properties | 1,090,690 |  |  | 1,050,247 |
Less accumulated depreciation | (211,058) |  |  | (200,810) |
Total real estate properties, net | 879,632 |  |  | 849,437 |
Cash and cash equivalents | 3,805 |  |  | 3,491 |
Restricted cash | 1,141 |  |  | 1,142 |
Real estate properties held for sale | 7,466 |  |  | 7,466 |
Other assets, net | 90,657 |  |  | 83,876 |
Total assets | $ | 982,701 |  |  | $ | 945,412 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
Liabilities |  |  |
Debt, net | $ | 442,320 |  |  | $ | 403,256 |
Accounts payable and accrued liabilities | 11,775 |  |  | 12,032 |
Other liabilities, net | 16,960 |  |  | 16,868 |
Total liabilities | 471,055 |  |  | 432,156 |
Commitments and contingencies |  |  |
Stockholders' Equity |  |  |
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding | — |  |  | — |
Common stock, $0.01 par value; 450,000 shares author ized; 27,701 and 27,613 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 277 |  |  | 276 |
Additional paid-in capital | 690,491 |  |  | 688,156 |
Cumulative net income | 92,521 |  |  | 88,856 |
Accumulated other comprehensive income | 21,490 |  |  | 16,417 |
Cumulative dividends | (293,133) |  |  | (280,449) |
Total stockholders’ equity | 511,646 |  |  | 513,256 |
Total liabilities and stockholders' equity | $ | 982,701 |  |  | $ | 945,412 |

See accompanying notes to the condensed consolidated financial statements.
3

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(Unaudited; Dollars and shares in thousands, except per share amounts)

| Three Months Ended March 31, |  |
| 2024 |  | 2023 |  |  |  |
REVENUES |  |  |  |  |  |  |
Rental income | $ | 28,342 |  |  | $ | 26,128 |  |  |  |  |
Other operating interest | 991 |  |  | 1,048 |  |  |  |  |
| 29,333 |  |  | 27,176 |  |  |  |  |
EXPENSES |  |  |  |  |  |  |
Property operating | 5,791 |  |  | 4,873 |  |  |  |  |
General and administrative (1) | 4,554 |  |  | 16,205 |  |  |  |  |
Depreciation and amortization | 10,262 |  |  | 9,018 |  |  |  |  |
| 20,607 |  |  | 30,096 |  |  |  |  |
OTHER INCOME (EXPENSE) |  |  |  |  |  |  |
Interest expense | (5,062) |  |  | (3,992) |  |  |  |  |
Deferred income tax expense | — |  |  | (35) |  |  |  |  |
Interest and other income | 1 |  |  | 25 |  |  |  |  |
| (5,061) |  |  | (4,002) |  |  |  |  |
NET INCOME (LOSS) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
NET INCOME (LOSS) PER COMMON SHARE |  |  |  |  |  |  |
Net income (loss) per common share - Basic | $ | 0.11 |  |  | $ | (0.32) |  |  |  |  |
Net income (loss) per common share - Diluted | $ | 0.11 |  |  | $ | (0.32) |  |  |  |  |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC | 26,297 |  |  | 24,227 |  |  |  |  |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED | 26,297 |  |  | 24,227 |  |  |  |  |
___________ |  |  |  |  |  |  |
(1) General and administrative expenses for the three months ended March 31, 2024 included stock-based compensation expense totaling approximately $2.4 million. General and administrative expenses for the three months ended March 31, 2023 included stock-based compensation expense totaling approximately $14.3 million, including the accelerated amortization of stock-based compensation totaling approximately $11.8 million recognized upon the passing of our former CEO and President in the first quarter of 2023. See Note 9 – Stock Incentive Plan.

See accompanying notes to the condensed consolidated financial statements.
4

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(Unaudited; Dollars in thousands)

|  |  | Three Months Ended March 31, |  |
|  |  | 2024 |  | 2023 |  |  |  |
NET INCOME (LOSS) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
| Other comprehensive income (loss): |  |  |  |  |  |  |
|  | Increase (decrease) in fair value of cash flow hedges | 7,870 |  |  | (4,973) |  |  |  |  |
|  | Reclassification for amounts recognized as interest expense | (2,797) |  |  | (2,010) |  |  |  |  |
| Total other comprehensive income (loss) | 5,073 |  |  | (6,983) |  |  |  |  |
COMPREHENSIVE INCOME (LOSS) | $ | 8,738 |  |  | $ | (13,905) |  |  |  |  |

See accompanying notes to the condensed consolidated financial statements.
5

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2024
(Unaudited; Dollars and shares in thousands, except per share amounts)

| Preferred Stock |  | Common Stock |  | Additional Paid in Capital |  | Cumulative Net Income |  | Accumulated Other Comprehensive Income |  | Cumulative Dividends |  | Total Stockholders' Equity
| Shares | Amount |  | Shares | Amount |
Balance at December 31, 2023 | — |  | $ | — |  |  | 27,613 | $ | 276 |  |  | $ | 688,156 |  |  | $ | 88,856 |  |  | $ | 16,417 |  |  | $ | (280,449) |  |  | $ | 513,256 |
Issuance of common stock, net of issuance costs | — |  | — |  |  | 19 |  | — |  |  | 463 |  |  | — |  |  | — |  |  | — |  |  | 463 |
Stock-based compensation, net of forfeitures | — |  | — |  |  | 90 |  | 1 |  |  | 2,423 |  |  | — |  |  | — |  |  | — |  |  | 2,424 |
Shares withheld on vesting of stock-based compensation | — |  | — |  |  | (21) |  | — |  |  | (551) |  |  | — |  |  | — |  |  | — |  |  | (551) |
Increase in fair value of cash flow hedges | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | 7,870 |  |  | — |  |  | 7,870 |
Reclassification for amounts recognized as interest expense | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | (2,797) |  |  | — |  |  | (2,797) |
Net income | — |  | — |  |  | — | — |  |  | — |  |  | 3,665 |  |  | — |  |  | — |  |  | 3,665 |
Dividends to common stockholders ($0.4575 per share) | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | — |  |  | (12,684) |  |  | (12,684) |
Balance at March 31, 2024 | — |  | $ | — |  |  | 27,701 | $ | 277 |  |  | $ | 690,491 |  |  | $ | 92,521 |  |  | $ | 21,490 |  |  | $ | (293,133) |  |  | $ | 511,646 |

See accompanying notes to the condensed consolidated financial statements.
6

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2023
(Unaudited; Dollars and shares in thousands, except per share amounts)

| Preferred Stock |  | Common Stock |  | Additional Paid in Capital |  | Cumulative Net Income |  | Accumulated Other Comprehensive Income |  | Cumulative Dividends |  | Total Stockholders' Equity
| Shares | Amount |  | Shares | Amount |
Balance at December 31, 2022 | — |  | $ | — |  |  | 25,897 | $ | 259 |  |  | $ | 625,136 |  |  | $ | 81,142 |  |  | $ | 22,667 |  |  | $ | (232,390) |  |  | $ | 496,814 |
Issuance of common stock, net of issuance costs | — |  | — |  |  | 249 | 3 |  |  | 8,903 |  |  | — |  |  | — |  |  | — |  |  | 8,906 |
Stock-based compensation, net of forfeitures | — |  | — |  |  | 128 | 1 |  |  | 14,345 |  |  | — |  |  | — |  |  | — |  |  | 14,346 |
Decrease in fair value of cash flow hedges | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | (4,973) |  |  | — |  |  | (4,973) |
Reclassification for amounts recognized as interest expense | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | (2,010) |  |  | — |  |  | (2,010) |
Net loss | — |  | — |  |  | — | — |  |  | — |  |  | (6,922) |  |  | — |  |  | — |  |  | (6,922) |
Dividends to common stockholders ($0.4475 per share) | — |  | — |  |  | — | — |  |  | — |  |  | — |  |  | — |  |  | (11,646) |  |  | (11,646) |
Balance at March 31, 2023 | — |  | $ | — |  |  | 26,274 | $ | 263 |  |  | $ | 648,384 |  |  | $ | 74,220 |  |  | $ | 15,684 |  |  | $ | (244,036) |  |  | $ | 494,515 |

See accompanying notes to the condensed consolidated financial statements.
7

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in thousands)

| Three Months Ended March 31,
| 2024 |  | 2023
OPERATING ACTIVITIES |  |  |
Net income (loss) | $ | 3,665 |  |  | $ | (6,922) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
Depreciation and amortization | 10,262 |  |  | 9,018 |
Other amortization | 217 |  |  | 265 |
Stock-based compensation | 2,424 |  |  | 2,547 |
Accelerated amortization of stock-based compensation | — |  |  | 11,799 |
Straight-line rent receivable | (755) |  |  | (917) |
Deferred income tax expense | — |  |  | 35 |
Changes in operating assets and liabilities: |  |  |
Other assets | (2,056) |  |  | (2,390) |
Accounts payable and accrued liabilities | (1,079) |  |  | 133 |
Other liabilities | (35) |  |  | (870) |
Net cash provided by operating activities | 12,643 |  |  | 12,698 |
INVESTING ACTIVITIES |  |  |
Acquisitions of real estate | (34,297) |  |  | (23,895) |
Funding of notes receivable | — |  |  | (1,295) |
Proceeds from the repayment of notes receivable | 870 |  |  | 750 |
Capital expenditures on existing real estate properties | (5,113) |  |  | (4,138) |
Net cash used in investing activities | (38,540) |  |  | (28,578) |
FINANCING ACTIVITIES |  |  |
Net borrowings on revolving credit facility | 39,000 |  |  | 12,000 |
Mortgage note repayments | (32) |  |  | (32) |
Dividends paid | (12,684) |  |  | (11,646) |
Proceeds from issuance of common stock | 540 |  |  | 8,215 |
Taxes paid on behalf of employees and shares withheld upon shares vesting | (551) |  |  | — |
Equity issuance costs | (63) |  |  | (100) |
Net cash provided by financing activities | 26,210 |  |  | 8,437 |
Increase (decrease) in cash, cash equivalents and restricted cash | 313 |  |  | (7,443) |
Cash, cash equivalents and restricted cash, beginning of period | 4,633 |  |  | 12,068 |
Cash, cash equivalents and restricted cash, end of period | $ | 4,946 |  |  | $ | 4,625 |
Supplemental Cash Flow Information: |  |  |
Interest paid (net of capitalized interest) | $ | 4,790 |  |  | $ | 3,866 |
Invoices accrued for construction, tenant improvement and other capitalized costs | $ | 4,591 |  |  | $ | 3,274 |
Reclassification of registration statement costs incurred in prior years to equity issuance costs | $ | 72 |  |  | $ | 52 |
Increase (decrease) in fair value of cash flow hedges | $ | 7,870 |  |  | $ | (4,973) |
Income taxes paid | $ | 26 |  |  | $ | 60 |
Capitalized interest | $ | 28 |  |  | $ | 192 |
Net proceeds accrued for common stock issued in March with cash settlement in April | $ | — |  |  | $ | 732 |

See accompanying notes to the condensed consolidated financial statements.
8

COMMUNITY HEALTHCARE TRUST INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2024
(Unaudited)
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Overview
Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of March 31, 2024, the Company had investments of approximately $1.1 billion in 197 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and two properties classified as an asset held for sale with an aggregate amount totaling approximately $7.5 million. See Note 10 – Other Assets, net and Note 4 – Real Estate Acquisitions and Dispositions, respectively). The properties are located in 35 states, totaling approximately 4.4 million square feet in the aggregate and were approximately 92.3% leased, excluding real estate assets held for sale, at March 31, 2024 with a weighted average remaining lease term of approximately 6.9 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review.
Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes, including among others, estimates related to impairment assessments, purchase price allocations, valuation of properties held for sale, and valuation of financial instruments. Actual results may materially differ from those estimates.
Cash and Cash Equivalents and Restricted Cash
Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Company's Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows:

| Balance as of March 31,
(Dollars in thousands) | 2024 |  | 2023
Cash and cash equivalents | $ | 3,805 |  |  | $ | 3,666 |
Restricted cash | 1,141 |  |  | 959 |
Cash, cash equivalents and restricted cash | $ | 4,946 |  |  | $ | 4,625 |

9

Notes to Condensed Consolidated Financial Statements - Continued
Revenue Recognition
The primary source of revenue for the Company is generated through its leasing arrangements with its tenants which is accounted for under ASC Topic 842, or through notes with its borrowers which is covered under ASC 310. The Company's rental income and interest income are recognized based on contractual arrangements with its tenants and borrowers. From the inception of a lease, if collection of substantially all of the lease payments is probable for a tenant, then rental income is recognized as earned over the life of the lease agreement on a straight-line basis. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue in amounts more or less than amounts currently due from tenants. If management determines that collection of substantially all of a lease’s payments is not probable, it will revert to recognizing such lease payments at the lesser of cash collected, lease income reflected on a straight-line basis, or another systematic basis plus variable rent when it becomes accruable and will reverse any recorded receivables related to that lease. In the event that management subsequently determines collection of substantially all of that lease’s receivable is probable, management will reinstate and record all such receivables for the lease in accordance with the lease terms. The Company maintains a general allowance for its lease receivables that the Company has determined are probable of collection. The Company recognizes interest income on an accrual basis unless the Company determines that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis.
Income Taxes
The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes. No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP) and meet other requirements to continue to qualify as a REIT.
NOTE 2. REAL ESTATE INVESTMENTS
As of March 31, 2024, we had investments of approximately $1.1 billion in 197 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and two properties classified as held for sale with an aggregate amount totaling approximately $7.5 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:

Property Type | # of Properties | Gross Investment (in thousands)
Medical Office Building | 96 |  | $ | 469,475 |
Inpatient Rehabilitation Hospitals | 8 |  | 174,772 |
Acute Inpatient Behavioral | 5 |  | 130,528 |
Specialty Centers | 37 |  | 117,807 |
Physician Clinics | 30 |  | 87,873 |
Surgical Centers and Hospitals | 10 |  | 54,181 |
Behavioral Specialty Facilities | 9 |  | 45,051 |
Long-term Acute Care Hospitals | 2 |  | 21,484 |
Total | 197 |  | $ | 1,101,171 |

10

Notes to Condensed Consolidated Financial Statements - Continued

State | # of Properties | Gross Investment (in thousands)
Texas | 17 |  | $ | 162,944 |
Illinois | 18 |  | 131,956 |
Ohio | 26 |  | 114,169 |
Florida | 25 |  | 109,490 |
Pennsylvania | 15 |  | 59,531 |
All Others | 96 |  | 523,081 |
Total | 197 |  | $ | 1,101,171 |

Primary Tenant | # of Properties | Gross Investment (in thousands)
Lifepoint Health | 6 |  | $ | 105,862 |
US HealthVest | 3 |  | 77,964 |
All Others (less than 4%) | 188 |  | 917,345 |
Total | 197 |  | $ | 1,101,171 |

GenesisCare Bankruptcy
Effective February 16, 2024, one of the Company's tenants, GenesisCare and certain of its affiliates ("GenesisCare"), emerged from Chapter 11 bankruptcy protection, and GenesisCare U.S. is now an independent business delivering oncology and specialty care services in Florida and North Carolina. Of the Company's seven leases with GenesisCare, five were assumed or assigned to buyers as part of the bankruptcy process and two remain with the GenesisCare U.S. entity.
NOTE 3. REAL ESTATE LEASES
Lessor Accounting
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2039. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property.
Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease.
Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of March 31, 2024, are as follows (in thousands):

2024 (nine months ended December 31) | $ | 74,362 |
2025 | 93,815 |
2026 | 84,865 |
2027 | 77,227 |
2028 | 71,052 |
2029 and thereafter | 381,758 |
| $ | 783,079 |

Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent included in rental income was approximately $0.8 million and $0.9 million, respectively, for the three months ended March 31, 2024 and 2023.
11

Notes to Condensed Consolidated Financial Statements - Continued
Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At March 31, 2024, the Company had an aggregate gross investment of approximately $37.2 million in 10 real estate properties with purchase options exercisable at March 31, 2024 that had not been exercised.
Sales-type Lease
The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of March 31, 2024, are as follows (in thousands):

2024 (nine months ended December 31) | $ | 261 |
2025 | 356 |
2026 | 367 |
2027 | 378 |
2028 | 389 |
2029 and thereafter | 4,821 |
Total undiscounted lease receivable | 6,572 |
Discount | (3,547) |
Lease receivable | $ | 3,025 |

The Company recognized interest income of approximately $0.1 million during each of the three months ended March 31, 2024 and 2023 related to this lease which is included in other operating interest on the Company's Condensed Consolidated Statements of Income.
Lessee Accounting
At March 31, 2024, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):

| Operating | Financing
2024 (nine months ended December 31) | $ | 32 |  | $ | 115 |
2025 | 44 |  | 154 |
2026 | 44 |  | 154 |
2027 | 45 |  | 154 |
2028 | 46 |  | 154 |
2029 and thereafter | $ | 1,102 |  | $ | 6,802 |
Total undiscounted lease payments | 1,313 |  | 7,533 |
Discount | (541) |  | (4,260) |
Lease liabilities | $ | 772 |  | $ | 3,273 |

12

Notes to Condensed Consolidated Financial Statements - Continued
The following table discloses other information regarding the ground leases.

| Three Months Ended March 31,
| 2024 | 2023
Operating leases: |  |
Weighted-average remaining lease term in years (including renewal options) | 34.8 | 36.0
Weighted-average discount rate | 4.0 | % | 4.0 | %
Financing leases: |  |
Weighted-average remaining lease term in years (including renewal options) | 39.6 | 40.6
Weighted-average discount rate | 4.2 | % | 4.2 | %

NOTE 4. REAL ESTATE ACQUISITIONS AND DISPOSITIONS
Acquisitions
During the first quarter of 2024, the Company acquired four real estate properties in three transactions. Upon acquisition, the properties were 98.6% leased in the aggregate with lease expirations through 2039. Amounts reflected in revenues and net income for these properties for the three months ended March 31, 2024 were approximately $0.2 million and $0.1 million, respectively, and transaction costs totaling approximately $0.3 million were capitalized relating to these property acquisitions.
The following table summarizes our property acquisitions for the three months ended March 31, 2024:

Location | Property Type (1) | Number of Properties | Date Acquired | Purchase Price | Cash Consideration | Real Estate | Other (2) | Square Footage
|  |  |  | (000's) | (000's) | (000's) | (000's) |
New Bedford, MA | LTACH | 1 | 1/31/24 | $ | 6,500 |  | $ | 6,540 |  | $ | 6,547 |  | $ | (7) |  | 70,657 |
Elkton, MD | MOB | 1 | 3/25/24 | 4,500 |  | 4,578 |  | 4,757 |  | (179) |  | 19,656 |
Bemidji, MN | MOB | 2 | 3/29/24 | 23,200 |  | 23,179 |  | 23,375 |  | (196) |  | 74,700 |
|  |  |  | $ | 34,200 |  | $ | 34,297 |  | $ | 34,679 |  | $ | (382) |  | 165,013 |
(1) LTACH - Long-term Acute Care Hospital; MOB - Medical Office Building
(2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition

The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the three months ended March 31, 2024:

|  |  | Relative Fair Value | Estimated Useful Life
|  |  | (in thousands) | (in years)
Land and land improvements | $ | 4,597 |  | 5.1
Building and building improvements | 27,538 |  | 26.7
Intangibles: |  |
| At-market lease intangibles | 2,544 |  | 3.6
| Above-market lease intangibles | 121 |  | 5.0
| Below-market lease intangibles | (275) |  | 2.0
|  | Total intangibles | 2,390 |  |
Accounts payable, accrued liabilities and other liabilities assumed | (194) |  |
Accounts receivable and other assets acquired | 48 |  |
Prorated rent, interest and operating expense reimbursement amounts collected | (82) |  |
| Total cash consideration | $ | 34,297 |  |

13

Notes to Condensed Consolidated Financial Statements - Continued
Assets Held for Sale
The Company had two properties classified as held for sale as of March 31, 2024. The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023.

(Dollars in thousands) | March 31, 2024 |  | December 31, 2023
Balance Sheet data: |  |  |
Land | $ | 1,576 |  |  | $ | 1,576 |
Building, improvements, and lease intangibles | 10,056 |  |  | 10,056 |
| 11,632 |  |  | 11,632 |
Accumulated depreciation | (4,166) |  |  | (4,166) |
Real estate assets held for sale, net | $ | 7,466 |  |  | $ | 7,466 |

NOTE 5. DEBT, NET
The table below details the Company's debt as of March 31, 2024 and December 31, 2023.

| Balance as of |
(Dollars in thousands) | March 31, 2024 | December 31, 2023 | Maturity Dates
Credit Facility: |  |  |
Revolving Credit Facility | $ | 89,000 |  | $ | 50,000 |  | 3/26
A-3 Term Loan, net | 74,761 |  | 74,730 |  | 3/26
A-4 Term Loan, net | 124,550 |  | 124,522 |  | 3/28
A-5 Term Loan, net | 149,222 |  | 149,189 |  | 3/30
Mortgage Note Payable, net | 4,787 |  | 4,815 |  | 5/24
| $ | 442,320 |  | $ | 403,256 |  |

Credit Facility
The Company's third amended and restated credit agreement, as amended (the "Credit Facility") is by and among
Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent.
The Credit Facility provides for a $150.0 million revolving credit facility (the "Revolving Credit Facility") and $350.0 million in term loans (the "Term Loans"). The Revolving Credit Facility matures on March 19, 2026 and includes one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which matures on March 29, 2026, a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and a seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan") which matures on March 14, 2030. Loans under the Credit Facility are interest only with principal amounts due as of each facility's applicable maturity date. The Credit Facility allows the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility.
Amounts outstanding under the Revolving Credit Facility will bear interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. The Company had $89.0 million outstanding under the
14

Notes to Condensed Consolidated Financial Statements - Continued
Revolving Credit Facility with a weighted average interest rate of 7.06% and a borrowing capacity remaining of $61.0 million at March 31, 2024.
Amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.65% to 2.30%, plus a simple SOFR adjustment equal to 0.10% per annum, or (ii) a base rate plus 0.65% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps. At March 31, 2024, the Company had $350.0 million outstanding under the Term Loans which had a fixed weighted average interest rate under the swaps of approximate ly 4.4%.
The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of March 31, 2024.
Mortgage Note Payable
The Company's mortgage note payable is secured by a building which had a $7.1 million carrying balance at March 31, 2024. The mortgage note amortizes monthly at a fixed interest rate of 4.98% with a balloon payment of approximately $4.8 million due upon maturity on May 1, 2024.
NOTE 6. DERIVATIVE FINANCIAL INSTRUMENTS
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations.
Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.
On March 29, 2024, two interest rate swaps matured and were replaced with two forward-starting interest rate swaps for notional amounts totaling $50.0 million. As of March 31, 2024, the Company had fifteen outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, which mature between 2026 and 2030, at the maturity dates of the associated term loans (see Note 5 – Debt, net).
15

Notes to Condensed Consolidated Financial Statements - Continued
Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.

| Asset Derivatives Fair Value at |  | Liability Derivatives Fair Value at
(Dollars in thousands) | March 31, 2024 | December 31, 2023 | Balance Sheet Classification |  | March 31, 2024 | December 31, 2023 | Balance Sheet Classification
Interest rate swaps | $ | 21,490 |  | $ | 16,417 |  | Other assets, net |  | $ | — |  | $ | — |  | Other liabilities, net

The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings.
Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $9.2 million will be reclassified from AOCI as a decrease to interest expense.
Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income
The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three months ended March 31, 2024 and 2023.

| Three Months Ended March 31, |  |
(Dollars in thousands) | 2024 | 2023 |  |  |
Amount of unrealized gain (loss) recognized in OCI on derivative | $ | 7,870 |  | $ | (4,973) |  |  |  |
Amount of gain reclassified from AOCI into interest expense | $ | (2,797) |  | $ | (2,010) |  |  |  |
Total interest expense presented in the Condensed Consolidated Statements of Income in which the effects of the cash flow hedges are recorded | $ | 5,062 |  | $ | 3,992 |  |  |  |

Tabular Disclosures of Offsetting Derivatives
The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of March 31, 2024 and December 31, 2023. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets.

Offsetting of Derivative Assets (as of March 31, 2024)
|  |  |  | Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) | Gross Amounts of Recognized Assets | Gross Amounts Offset in the Condensed Consolidated Balance Sheet | Net Amounts of Assets in the Condensed Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received | Net Amount
Derivatives | $ | 21,490 |  | $ | — |  | $ | 21,490 |  | $ | — |  | $ | — |  | $ | 21,490 |

Offsetting of Derivative Liabilities (as of March 31, 2024)
|  |  |  | Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) | Gross Amounts of Recognized Liabilities | Gross Amounts Offset in the Condensed Consolidated Balance Sheet | Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received | Net Amount
Derivatives | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |

16

Notes to Condensed Consolidated Financial Statements - Continued

Offsetting of Derivative Assets (as of December 31, 2023)
|  |  |  | Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) | Gross Amounts of Recognized Assets | Gross Amounts Offset in the Condensed Consolidated Balance Sheet | Net Amounts of Assets in the Condensed Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received | Net Amount
Derivatives | $ | 16,417 |  | $ | — |  | $ | 16,417 |  | $ | — |  | $ | — |  | $ | 16,417 |

Offsetting of Derivative Liabilities (as of December 31, 2023)
|  |  |  | Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) | Gross Amounts of Recognized Liabilities | Gross Amounts Offset in the Condensed Consolidated Balance Sheet | Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received | Net Amount
Derivatives | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |

Credit-risk-related Contingent Features
As of March 31, 2024, the Company did not have any derivatives in a net liability position. As of March 31, 2024, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.
NOTE 7. STOCKHOLDERS' EQUITY
Common Stock
The following table provides a reconciliation of the beginning and ending common stock balances for the three months ended March 31, 2024 and for the year ended December 31, 2023:

(In thousands) | Three Months Ended March 31, 2024 | Year Ended December 31, 2023
Balance, beginning of period | 27,613 | 25,897
Issuance of common stock | 19 | 1,385
Restricted stock issued | 90 | 361
Restricted stock withheld and forfeited | (21) | (30)
Balance, end of period | 27,701 | 27,613

ATM Program
The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC, as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $500.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law.
17

Notes to Condensed Consolidated Financial Statements - Continued
The Company's activity under the ATM Program during the three months ended March 31, 2024 is detailed in the table below. As of March 31, 2024, the Company had approximately $433.3 million remaining that may be issued under the ATM Program.

| Three Months Ended March 31, 2024 |
Shares issued (in thousands) | 19 |
Net proceeds received (in millions) | $0.5 |
Average gross sales price per share | $27.51 |

NOTE 8. NET INCOME (LOSS) PER COMMON SHARE
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2024 and 2023, respectively.

| Three Months Ended March 31, |  |
(In thousands, except per share data) | 2024 |  | 2023 |  |  |  |
Net income (loss) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
Participating securities' share in earnings | (647) |  |  | (822) |  |  |  |  |
Net income (loss), less participating securities' share in earnings | $ | 3,018 |  |  | $ | (7,744) |  |  |  |  |
Weighted average Common Shares outstanding |  |  |  |  |  |  |
Weighted average Common Shares outstanding | 27,680 |  |  | 26,043 |  |  |  |  |
Unvested restricted shares | (1,383) |  |  | (1,816) |  |  |  |  |
Weighted average Common Shares outstanding–Basic | 26,297 |  |  | 24,227 |  |  |  |  |
Dilutive potential common shares | — |  |  | — |  |  |  |  |
Weighted average Common Shares outstanding –Diluted | 26,297 |  |  | 24,227 |  |  |  |  |
Basic Net Income (Loss) per Common Share | $ | 0.11 |  |  | $ | (0.32) |  |  |  |  |
Diluted Net Income (Loss) per Common Share | $ | 0.11 |  |  | $ | (0.32) |  |  |  |  |

NOTE 9. STOCK INCENTIVE PLAN
A summary of the restricted stock activity under the Company's 2014 Incentive Plan, as amended, for the three months ended March 31, 2024 and 2023 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods.

|  | Three Months Ended March 31, |  |
(Dollars and shares in thousands) | 2024 | 2023 |  |  |
Stock-based awards, beginning of period | 1,374 |  | 1,708 |  |  |  |
| Stock in lieu of compensation | 43 |  | 62 |  |  |  |
| Stock awards | 47 |  | 67 |  |  |  |
| Total stock granted | 90 |  | 129 |  |  |  |
| Vested shares (1) | (84) |  | — |  |  |  |
| Forfeited shares | — |  | (1) |  |  |  |
Stock-based awards, end of period | 1,380 |  | 1,836 |  |  |  |
Amortization expense (1) | $ | 2,107 |  | $ | 14,346 |  |  |  |
___________ |
1) Amortization expense for the three months ended March 31, 2023 included accelerated amortization totaling approximately $11.8 million upon the passing of our former CEO and President.

18

Notes to Condensed Consolidated Financial Statements - Continued
Accelerated Amortization of Restricted Stock
The Company's former CEO and President, Timothy Wallace, passed away in March 2023. At the time of his passing, Mr. Wallace had 624,725 shares of restricted stock that had not been fully amortized. In accordance with the terms of his employment agreement, the Company accelerated the unamortized remaining balance of deferred compensation related to his unvested shares and recognized an additional $11.8 million of amortization expense in the first quarter of 2023.
Amendment to the 2014 Incentive Plan, Updates to Compensation Programs, and Issuance of RSUs
On January 2, 2024, the Company's Board approved and adopted a fourth amendment to the 2014 Incentive Plan that provided for the award of restricted stock units ("RSUs").
The Board also approved and adopted the Third Amended and Restated Alignment of Interest Program (the "Third Alignment of Interest Program"), which superseded the Second Amended and Restated Alignment of Interest Program. The Third Alignment of Interest Program implemented (i) a maximum elective deferral percentage amount of salary and bonus to 50% to the acquisition of restricted stock for certain participants in the program (previously 100%), and (ii) limited the duration of the restriction period election depending on the retirement eligibility date per their employment agreements. These changes were effective beginning January 1, 2024 for salary and other compensation deferrals and will be effective for performance periods commencing on and after July 1, 2024 for cash bonus deferrals.
Further, the Board approved and adopted the Third Amended and Restated Executive Officer Incentive Program (the "Third Executive Officer Incentive Program"), which superseded the Second Amended and Restated Executive Officer Program, other than with respect to the individual and company performance awards for the performance period running from July 1, 2023 to June 30, 2024. The Third Executive Officer Incentive Program allows for the grant of RSUs.
The Company historically granted long-term incentive awards to its executive officers which was comprised of restricted stock that vested in 8 years, based on backward-looking performance metrics. On January 2, 2024, the Board approved and adopted a new incentive compensation structure for its executive officers, including the issuance of time-based and performance-based RSUs with three-year forward-looking performance targets beginning with an initial performance period beginning July 1, 2023.
On January 2, 2024, the Company granted performance-based and time-based RSUs to its executive officers under the 2014 Incentive Plan and the Third Executive Officer Incentive Program. These RSUs with a grant date value totaling $2.6 million are forward-looking with a three-year performance period beginning July 1, 2023. The performance-based RSUs were valued by independent specialists utilizing a Monte Carlo simulation to calculate the weighted average grant date fair values of $13.67 per share for the Absolute TSR units and $20.77 per share for the Relative TSR units. The grant date fair value of the Time-based TSR units was based on the Company's stock price on the grant date of $26.62. The combined weighted average grant date fair value of the RSUs granted was $19.24 per share. The following assumptions were used in valuing the performance-based RSUs:

Volatility | 25.0 | % |  |  |
Dividend assumption | 5.4 | % |  |  |
Expected term | 3 years |  |  |
Risk-free rate | 4.3 | % |  |  |
Stock price (per share) | $ | 26.62 |  |  |  |

19

Notes to Condensed Consolidated Financial Statements - Continued
A summary of the Company's RSU activity during the three months ended March 31, 2024 and 2023, respectively, is included in the table below, as well as compensation expense recognized from the amortization of the value of RSUs over the applicable vesting periods.

|  | Three Months Ended March 31,
(Dollars and RSUs in thousands) | 2024 | 2023
Restricted Stock Units, beginning of period | — |  | — |
| Absolute TSR Performance-based RSUs granted | 57 |  | — |
| Relative TSR Performance-based RSUs granted | 43 |  | — |
| Time-based RSUs granted | 34 |  | — |
| Total RSUs granted | 134 |  | — |
| Vested RSUs | — |  | — |
| Forfeited RSUs | — |  | — |
Restricted Stock Units, end of period | 134 |  | — |
Amortization expense | $ | 317 |  | $ | — |
Grant Date Value Remaining at period end to be Amortized During the Performance Period | $ | 2,253 |  | $ | — |
______________
(1) The number of Performance-based RSUs granted were based on target levels. Actual number of shares granted will be based on performance at the end of the performance period which is June 30, 2026. The Performance-based RSUs, if earned, will vest at the end of the performance period.
(2) The number of Time-based RSUs granted were based on target levels. One-third of these RSUs will vest on each of June 30, 2024, 2025, 2026.

Restricted Stock Issuances
On January 12, 2024, pursuant to the 2014 Incentive Plan and the Third Alignment of Interest Program, the Company granted 79,533 shares of restricted stock to its employees, in lieu of salary, that will cliff vest between three and eight years. Of the shares granted, 43,292 shares of restricted stock were granted in lieu of compensation from the program pool and 36,241 shares of restricted stock were awarded based on the restriction period elected from the plan pool. Also, on January 12, 2024, pursuant to the 2014 Incentive Plan and the Non-Executive Officer Incentive Program, the Company granted 10,159 shares of restricted stock to certain employees that will cliff vest in five years.
Adoption of the 2024 Incentive Plan
On March 4, 2024, the Company's Compensation Committee and Board of Directors adopted and approved the 2024 Incentive Plan (the "Plan"). On April 17, 2024, the Company's Board of Directors adopted and approved an amendment to the Plan to remove a sentence related to reload options. The Plan, as amended, is subject to approval by our stockholders at the annual meeting. The 2024 Incentive Plan, if approved, will replace our 2014 Incentive Plan which expired on March 31, 2024. The Plan, which will expire on March 4, 2034, implements several changes including, among others, the following:
•Freezes all awards under the 2014 Incentive Plan as of its expiration date;
•Removes the "evergreen provision" which allowed for the incremental automatic increase in the number of shares of common stock reserved for issuance under the Plan;
•Increases the number of shares of common stock authorize for issuance under the Plan to 1,150,000; and
•Expands the types of awards that may be awarded under the Plan.
20

Notes to Condensed Consolidated Financial Statements - Continued
NOTE 10. OTHER ASSETS, NET
Other assets, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 are detailed in the table below.

| Balance as of
(Dollars in thousands) | March 31, 2024 | December 31, 2023
Notes receivable | $ | 29,905 |  | $ | 30,775 |
Fair value of interest rate swaps | 21,490 |  | 16,417 |
Straight-line rent receivables | 19,236 |  | 18,481 |
Accounts receivable | 6,255 |  | 4,645 |
Sales-type lessor receivable | 3,025 |  | 3,028 |
Above-market intangible assets, net | 2,560 |  | 2,645 |
Leasing commissions, net | 2,498 |  | 2,312 |
Financing lease right-of-use assets | 2,471 |  | 2,486 |
Prepaid assets | 1,429 |  | 1,203 |
Operating lease right of use assets | 721 |  | 729 |
Other | 649 |  | 684 |
Deferred financing costs, net | 418 |  | 471 |
| $ | 90,657 |  | $ | 83,876 |

The Company's notes receivable mainly included:
•At March 31, 2024 and December 31, 2023, notes receivable included a $5.3 million and $6.0 million, respectively, term loan, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum.
•At March 31, 2024 and December 31, 2023, notes receivable included a fully-funded term loan totaling $17.0 million and a revolving credit facility with $5.4 million drawn, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. At March 31, 2024, the Company had an unfunded commitment of $3.1 million on the revolving credit facility and an unfunded commitment of up to $2.0 million on an advancing term loan facility. The term loan bears interest at 9% per annum, with interest only payments due initially and then equal monthly installments of principal payments due beginning March 31, 2025. The term loan facility matures on December 31, 2032. The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025. The advancing term loan may be funded at the Company's discretion, and bears interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note.
•At March 31, 2024 and December 31, 2023, notes receivable also included a $2.2 million and $2.3 million, respectively, revolving credit facility. Commencing on October 1, 2023, the revolving credit facility will be repaid in equal monthly installments of $40,000 through the maturity date of April 1, 2027. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note.
The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable.
21

Notes to Condensed Consolidated Financial Statements - Continued
The VIEs that we have identified at March 31, 2024 are summarized in the table below.

Classification | Carrying Amount (in thousands) | Maximum Exposure to Loss (in thousands)
Note receivable (term loan) | $ | 5,250 |  | $ | 5,250 |
Note receivable (revolving credit facility) | $ | 5,435 |  | $ | 5,435 |
Note receivable (term loan) | $ | 17,000 |  | $ | 17,000 |
Note receivable (revolving credit facility) | $ | 2,220 |  | $ | 2,220 |

NOTE 11. OTHER LIABILITIES, NET
Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 are detailed in the table below.

| Balance as of
(Dollars in thousands) | March 31, 2024 | December 31, 2023
Prepaid rent | $ | 5,442 |  | $ | 5,378 |
Security deposits | 3,789 |  | 3,765 |
Below-market lease intangibles, net | 3,185 |  | 3,188 |
Financing lease liability | 3,273 |  | 3,277 |
Operating lease liability | 772 |  | 775 |
Other | 499 |  | 485 |
| $ | 16,960 |  | $ | 16,868 |

NOTE 12. FAIR VALUE OF FINANCIAL INSTRUMENTS
The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value.
Cash and cash equivalents and restricted cash - The carrying amount approximates the fair value. The fair value estimates were determined using level 1 inputs.
Notes receivable - The fair value is estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and are classified as level 2 inputs in the hierarchy.
Borrowings under our Credit Facility - The carrying amount approximates the fair value because the borrowings are based on variable market interest rates. The fair value estimates were determined using level 2 inputs.
Derivative financial instruments (Interest rate swaps) - The fair value is estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs are utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps are observable in active markets and are classified as level 2 inputs in the hierarchy.
Mortgage note payable - The fair value is estimated using cash flow analyses which are based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and are classified as level 2 inputs in the hierarchy.
22

Notes to Condensed Consolidated Financial Statements - Continued
The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at March 31, 2024 and December 31, 2023, using level 2 inputs.

| March 31, 2024 |  | December 31, 2023
(Dollars in thousands) | Carrying Value | Fair Value |  | Carrying Value | Fair Value
Notes receivable | $ | 29,905 |  | $ | 30,738 |  |  | $ | 30,775 |  | $ | 31,199 |
Interest rate swap asset | $ | 21,490 |  | $ | 21,490 |  |  | $ | 16,417 |  | $ | 16,417 |
Mortgage note payable (principal amount) | $ | 4,788 |  | $ | 4,787 |  |  | $ | 4,821 |  | $ | 4,791 |

NOTE 13. COMMITMENTS AND CONTINGENCIES
Tenant Improvements
The Company may provide tenant improvement allowances in new or renewal leases for the purpose of refurbishing or renovating tenant space. The Company may also assume tenant improvement obligations included in leases acquired in its real estate acquisitions. As of March 31, 2024, the Company had approximately $22.5 million in commitments for tenant improvements. Seven of these projects totaling $15.8 million, represent redevelopment projects of the buildings into different healthcare uses backed by long term leases.
Capital Improvements
The Company has entered into contracts with various vendors for various capital improvement projects related to its portfolio. As of March 31, 2024, the Company had commitments of approximately $5.6 million in commitments for capital improvement projects.
Legal Proceedings
The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's Consolidated Financial Statements.
NOTE 14. SUBSEQUENT EVENTS
Dividend Declared
On April 25, 2024, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.46 per share. The dividend is payable on May 24, 2024 to stockholders of record on May 10, 2024.
Subsequent Acquisitions
Subsequent to March 31, 2024, the Company acquired one inpatient rehabilitation facility for a purchase price and cash consideration of approximately $23.5 million. Upon acquisition, the property was 100.0% leased with a lease expiration in 2039.
23

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Disclosure Regarding Forward-Looking Statements
This report and other materials that Community Healthcare Trust Incorporated (the "Company") has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “believes”, “expects”, “may”, "will', “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, “anticipates” or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Thus, the Company’s actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company’s common stock, changes in the Company’s business strategy, availability, terms and deployment of capital, the Company’s ability to refinance existing indebtedness at or prior to maturity on favorable terms, or at all, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company’s competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, rising interest rates, supply chain disruptions, labor conditions, the conflict between Russia and Ukraine, and/or new and ongoing hostilities between Israel and Hamas and the other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this report and the Company undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.
The purpose of this Management's Discussion and Analysis ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash. MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Condensed Consolidated Financial Statements and accompanying notes.
Overview
References such as "we," "us," "our," and "the Company" mean Community Healthcare Trust Incorporated, a Maryland corporation, and its consolidated subsidiaries.
We were organized in the State of Maryland on March 28, 2014. We are a self-administered, self-managed healthcare real estate investment trust, or REIT, that acquires and owns properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers.
Trends and Matters Impacting Operating Results
Management monitors factors and trends that it believes are important to the Company and the REIT industry in order to gauge their potential impact on the operations of the Company. Certain of the factors and trends that management believes may impact the operations of the Company are discussed below.
24

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Real Estate Acquisitions
During the three months ended March 31, 2024, the Company acquired four real estate properties totaling approximately 165,000 square feet for an aggregate purchase price of approximately $34.2 million and cash consideration of approximately $34.3 million. Upon acquisition, the properties were 98.6% leased in the aggregate with lease expirations through 2039. These acquisitions were funded through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility. See Note 4 – Real Estate Acquisitions and Dispositions to the Condensed Consolidated Financial Statements for more details on these acquisitions.
Subsequent Acquisitions
Subsequent to March 31, 2024, the Company acquired one inpatient rehabilitation facility for a purchase price and cash consideration of approximately $23.5 million. Upon acquisition, the property was 100.0% leased with a lease expiration in 2039.
Acquisition Pipeline
The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $169.5 million. The Company's expected return on these investments will approximate 9.1% to 9.75%. The Company anticipates closing on one of these properties in the fourth quarter of 2024 with the remainder throughout 2025, 2026 and 2027; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close.
Leased Square Footage
As of March 31, 2024, our real estate portfolio was approximately 92.3% leased. During the first three months of 2024, we had expiring or terminated leases related to approximately 143,000 square feet, and we leased or renewed leases relating to approximately 184,000 square feet.
Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase.
At March 31, 2024, the Company had an aggregate gross investment of approximately $37.2 million in 10 real estate properties with purchase options exercisable at March 31, 2024 that had not been exercised.
Inflation
Periods of high and persistent inflation could cause an increase in our expenses, capital expenditures, and cost of our variable-rate borrowings which could have a material impact on our financial position or results of operations. Many of our lease agreements contain provisions designed to mitigate the adverse impact of inflation, including annual rent increases based on stated increases or CPI increases. In response to inflationary pressures, the Federal Reserve began raising interest rates in 2022. Higher interest rates imposed by the Federal Reserve to address inflation may adversely impact real estate asset values and increase our interest expense on our variable-rate borrowings under our revolving credit facility.
Executive Compensation
During the first quarter of 2024, the Company's Board approved and adopted certain changes to executive compensation. Through the adoption of the Third Amended and Restated Alignment of Interest Program, the Board established a maximum elective deferral percentage amount of 50% (previously 100%) of compensation allowed to be deferred and applied to the acquisition of restricted stock for certain participants in the program, and limited the duration of the restriction period election depending on each individual's retirement eligibility date. These changes were effective beginning January 1, 2024 for salary and other compensation deferrals and will be effective for performance periods commencing on and after July 1, 2024 for cash bonus deferrals.
25

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Further, the Board approved and adopted a new long-term incentive compensation structure for its executive officers, which includes the issuance of time-based RSUs and performance-based RSUs with three-year forward-looking performance targets. Historically, the Company had granted long-term incentive awards to its executive officers comprised of restricted stock that vested in eight years, based on backward-looking performance metrics. See Note 9 – Stock Incentive Plan for more details.
Results of Operations
The Company's results of operations for the three months ended March 31, 2024 compared to the same period in 2023 were impacted by real estate acquisitions, the amortization of non-cash compensation, including the accelerated amortization of unvested restricted shares upon the passing of the Company's former CEO and President, the new executive compensation program, as well as other items discussed in more detail below.
Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023
The table below shows our results of operations for the three months ended March 31, 2024 compared to the same period in 2023 and the effect of changes in those results from period to period on our net income (loss).

| Three Months Ended March 31, |  | Increase (Decrease) to Net income
(Dollars in thousands) | 2024 |  | 2023 |  | $ | %
REVENUES |  |  |  |  |  |
Rental income | $ | 28,342 |  |  | $ | 26,128 |  |  | $ | 2,214 |  | 8.5 | %
Other operating interest | 991 |  |  | 1,048 |  |  | (57) |  | (5.4) | %
| 29,333 |  |  | 27,176 |  |  | 2,157 |  | 7.9 | %
EXPENSES |  |  |  |  |  |
Property operating | 5,791 |  |  | 4,873 |  |  | (918) |  | (18.8) | %
General and administrative | 4,554 |  |  | 16,205 |  |  | 11,651 |  | 71.9 | %
Depreciation and amortization | 10,262 |  |  | 9,018 |  |  | (1,244) |  | (13.8) | %
| 20,607 |  |  | 30,096 |  |  | 9,489 |  | 31.5 | %
OTHER INCOME (EXPENSE) |  |  |  |  |  |
Interest expense | (5,062) |  |  | (3,992) |  |  | (1,070) |  | (26.8) | %
Deferred income tax expense | — |  |  | (35) |  |  | 35 |  | 100.0 | %
Interest and other income, net | 1 |  |  | 25 |  |  | (24) |  | 96.0 | %
| (5,061) |  |  | (4,002) |  |  | (1,059) |  | 26.5 | %
NET INCOME (LOSS) | $ | 3,665 |  |  | $ | (6,922) |  |  | $ | 10,587 |  | n/m

___________
n/m-not meaningful
Revenues
Rental income increased approximately $2.2 million, or 8.5%, for the three months ended March 31, 2024 compared to the same period in 2023 due mainly to rental income on properties acquired during 2023 and 2024 resulting in additional rental income of approximately $2.9 million, with a $0.7 million decrease resulting substantially from lease expirations and terminations, including the two Genesis Care leases that were rejected in 2023 by Genesis Care as part of their bankruptcy.
Expenses
Property operating expenses increased approximately $0.9 million, or 18.8%, for the three months ended March 31, 2024 compared to the same period in 2023 due mainly to the following:
•Expenses on properties acquired during 2023 and 2024 increased property operating expenses by approximately $0.6 million;
26

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
•An increase in property operating expenses related to snow removal of approximately $0.2 million and insurance premiums of approximately $0.1 million.
General and administrative expenses decreased approximately $11.7 million, or 71.9%, for the three months ended March 31, 2024 compared to the same period in 2023 due mainly to the following:
•Non-cash stock-based compensation amortization expense decreased approximately $12.0 million for the three months ended March 31, 2024 compared to the same period in 2023;
◦In the first quarter of 2023, the Company accelerated the unamortized remaining balance of deferred compensation for unvested shares totaling $11.8 million upon the passing of the Company's former CEO and President, in accordance with the terms of his employment agreement.
◦Related to the new executive compensation program and the issuance of restricted stock units, the Company recognized non-cash amortization expense of approximately $0.3 million in the three months ended March 31, 2024.
◦The non-cash amortization of the restricted shares, other than the accelerated amortization discussed above, decreased approximately $0.4 million for the three months ended March 31, 2024 compared to the same period in 2023 due to the maximum deferral percentage change discussed in the next paragraph, the reduction of shares to the vesting of shares, including the shares held by our former CEO and President, offset by the issuance of additional restricted shares.
•Payroll-related expenses increased approximately $0.4 million for the three months ended March 31, 2024 compared to the same period in 2023. Approximately $0.3 million of this increase was related to the new executive compensation program which limited the maximum elective deferral percentage amount to 50% of salary allowed to be deferred. Also, in the first quarter of 2024, the Company paid approximately $0.1 million in payroll taxes related to the vesting of employee shares;
Depreciation and amortization e xpense increased approximately $1.2 million, or 13.8%, for the three months ended March 31, 2024 compared to the same period in 2023. This increase was comprised mainly of the following:
•Depreciation and amortization on real estate acquired during 2023 and 2024 resulted in an increase of approximately $1.4 million;
•Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $0.4 million; and
•Tenant improvements and other capital expenditures resulted in an increase of approximately $0.3 million
Interest expense
Interest expense increased approximately $1.1 million, or 26.8%, for the three months ended March 31, 2024 compared to the same period in 2023. Interest expense recognized on the credit facility for the three months ended March 31, 2024 compared to the same period in 2023 was higher due mainly to increases in the weighted average balance and interest rates on the revolving credit facility.
Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial
27

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.
The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.
Funds from Operations ("FFO") and Adjusted Funds from Operations ("AFFO")
FFO is an operating performance measure adopted by the National Association of Real Estate Investment Trusts, Inc. (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to net income (calculated in accordance with GAAP), excluding gains or losses from the sale of certain real estate assets, gains and losses from change in control, impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity, plus depreciation and amortization related to real estate properties, and after adjustments for unconsolidated partnerships and joint ventures. NAREIT also provides REITs with an option to exclude gains, losses and impairments of assets that are incidental to the main business of the REIT from the calculation of FFO.
In addition to FFO, the Company presents AFFO and AFFO per share. The Company defines AFFO as FFO, excluding certain expenses related to closing costs of properties acquired accounted for as business combinations and mortgages funded, excluding straight-line rent and the amortization of stock-based compensation, and including or excluding other non-cash items from time to time. AFFO presented herein may not be comparable to similar measures presented by other real estate companies due to the fact that not all real estate companies use the same definition.
Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO, AFFO, FFO per share and AFFO per share provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, losses and impairment of incidental assets, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO, AFFO, FFO per share and AFFO per share can facilitate comparisons of operating performance between periods.
28

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The table below reconciles net income (loss) to FFO and AFFO for the three months ended March 31, 2024 compared to the same period in 2023.

| Three Months Ended March 31, |  |
(In thousands, except per share amounts) | 2024 |  | 2023 |  |  |  |
Net income (loss) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
Real estate depreciation and amortization | 10,378 |  |  | 9,088 |  |  |  |  |
FFO | 14,043 |  |  | 2,166 |  |  |  |  |
Straight-line rent | (755) |  |  | (917) |  |  |  |  |
Stock-based compensation | 2,424 |  |  | 2,547 |  |  |  |  |
Accelerated amortization of stock-based compensation (1) | — |  |  | 11,799 |  |  |  |  |
AFFO | $ | 15,712 |  |  | $ | 15,595 |  |  |  |  |
FFO per diluted common share (1) | $ | 0.53 |  |  | $ | 0.09 |  |  |  |  |
AFFO per diluted common share | $ | 0.59 |  |  | $ | 0.62 |  |  |  |  |
Weighted average common shares outstanding - diluted (2) | 26,707 |  |  | 25,298 |  |  |  |  |

___________________
(1) In the first quarter of 2023, the Company accelerated the amortization of stock-based compensation totaling $11.8 million upon the passing of our former CEO and President, impacting FFO per diluted share by $0.47.
(2) Diluted weighted average common shares outstanding for FFO and AFFO are calculated based on the treasury method, rather than the 2-class method used to calculate earnings per share.
Net Operating Income ("NOI")
NOI is a key performance indicator. NOI is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, gains or loss on the sale of real estate properties or other investments, interest expense, and income tax expense. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. The Company's use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing NOI.
The table below reconciles net income (loss) to NOI for the three months ended March 31, 2024 compared to the same period in 2023.

|  | Three Months Ended March 31, |  |
(In thousands) | 2024 |  | 2023 |  |  |  |
Net income (loss) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
| General and administrative (1) | 4,554 |  |  | 4,406 |  |  |  |  |
| Accelerated amortization of stock-based compensation | — |  |  | 11,799 |  |  |  |  |
| Depreciation and amortization | 10,262 |  |  | 9,018 |  |  |  |  |
| Interest expense | 5,062 |  |  | 3,992 |  |  |  |  |
| Deferred income tax expense | — |  |  | 35 |  |  |  |  |
| Interest and other income | (1) |  |  | (25) |  |  |  |  |
NOI | $ | 23,542 |  |  | $ | 22,303 |  |  |  |  |
____________ |  |  |  |  |  |  |
(1) Excludes accelerated amortization of stock-based compensation shown separately in the reconciliation. |  |  |  |

EBITDA re and Adjusted EBITDA re
The Company uses the NAREIT definition of EBITDA re which is net income or loss plus interest expense, income tax expense, and depreciation and amortization, plus losses or minus gains on the disposition of depreciable property, including losses/gains on change of control, plus impairment write-downs of depreciable property and of investments in unconsolidated affiliates caused by a decrease in value of depreciable property in the affiliate, plus or
29

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
minus adjustments to reflect the entity's share of EBITDA re of unconsolidated affiliates and consolidated affiliates with non-controlling interest. The Company also presents Adjusted EBITDA re which is EBITDA re before non-cash stock-based compensation expense.
We consider EBITDA re and Adjusted EBITDA re important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.
The table below reconciles net income (loss) to EBITDA re and Adjusted EBITDA re for the three months ended March 31, 2024 compared to the same period in 2023.

|  | Three Months Ended March 31, |  |
(In thousands) | 2024 |  | 2023 |  |  |  |
Net income (loss) | $ | 3,665 |  |  | $ | (6,922) |  |  |  |  |
| Interest expense | 5,062 |  |  | 3,992 |  |  |  |  |
| Depreciation and amortization | 10,262 |  |  | 9,018 |  |  |  |  |
| Deferred income tax expense | — |  |  | 35 |  |  |  |  |
EBITDA re | $ | 18,989 |  |  | $ | 6,123 |  |  |  |  |
| Non-cash stock-based compensation expense (1) | 2,424 |  |  | 2,547 |  |  |  |  |
| Accelerated amortization of stock-based compensation | — |  |  | 11,799 |  |  |  |  |
Adjusted EBITDA re | $ | 21,413 |  |  | $ | 20,469 |  |  |  |  |
_____________ |  |  |  |
(1) Excludes accelerated amortization of stock-based compensation shown separately in the reconciliation. |  |  |  |

Liquidity and Capital Resources
The Company monitors its liquidity and capital resources and relies on several key indicators in its assessment of capital markets for financing acquisitions and other operating activities as needed, including the following:
•Leverage ratios and financial covenants included in our Credit Facility;
•Dividend payout percentage; and
•Interest rates, underlying treasury rates, debt market spreads and equity markets.
The Company uses these indicators and others to compare its operations to its peers and to help identify areas in which the Company may need to focus its attention.
Financing Policy
The Company’s current financing policy prohibits aggregate debt (secured or unsecured) in excess of 40% of the Company's total capitalization, except for short-term, transitory periods. At March 31, 2024, our debt to total capitalization ratio (debt plus stockholders' equity plus accumulated depreciation) was approximately 38.0%.
Sources and Uses of Cash
The Company derives most of its revenues from its real estate properties. Our rental income represents our primary source of liquidity to fund our dividends, general and administrative expenses, property operating expenses, capital improvements on our properties, interest expense on our Credit Facility, and other expenses incurred related to managing our existing portfolio. To the extent additional resources are needed, the Company will fund its investment activity generally through equity or debt issuances either in the public or private markets or through proceeds from our Credit Facility.
30

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The Company expects to meet its liquidity needs through cash on hand, cash flows from operations and cash flows from sources discussed above. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.
Credit Facility
The Company's Credit Facility provides for a $150.0 million Revolving Credit Facility that matures on March 19, 2026 and includes one 12-month option to extend the maturity date, and $350.0 million in Term Loans, as well as an accordion feature which allows borrowings up to a total of $700.0 million, including the ability to add and fund additional term loans. Note 5 – Debt, net to the Condensed Consolidated Financial Statements provides more details on the Company's Credit Facility. At March 31, 2024, the Company had borrowing capacity remaining under the Revolving Credit Facility of approximately $61.0 million.
The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of March 31, 2024.
Mortg age Note P ayable
The Company also had outstanding at March 31, 2024, a $4.8 million mortgage note payable, secured by one of its properties. The mortgage note amortizes monthly at a fixed interest rate of 4.98% with a balloon payment of approximately $4.8 million due upon maturity on May 1, 2024. The Company expects to fund the balloon payment with the Company's free cash flow or proceeds from the Company's Revolving Credit Facility.
Ground Leases
At March 31, 2024, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. At March 31, 2024, the Company's aggregate obligation under these ground leases was approximately $8.8 million. See Note 3 – Real Estate Leases to the Condensed Consolidated Financial Statements.
Subsequent Acquisitions
Subsequent to March 31, 2024, the Company acquired one inpatient rehabilitation facility for a purchase price and cash consideration of approximately $23.5 million. Upon acquisition, the property was 100.0% leased with a lease expiration in 2039. The acquisition was funded with proceeds from the Company's Revolving Credit Facility.
Acquisition Pipeline
The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $169.5 million. The Company anticipates closing on one of these properties in the fourth quarter of 2024 with the remainder throughout 2025, 2026 and 2027; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.
Tenant Improvements and Capital Improvements
Subject to Company approval, we may fund or reimburse tenants for tenant improvements, which are allowed for in certain leases, of up to approximately $22.5 million as of March 31, 2024. At March 31, 2024, seven of these projects, totaling $15.8 million, represented redevelopment projects on buildings with tenants backed by long term leases.
31

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The Company has also entered into contracts regarding certain capital expenditures with remaining commitments totaling approximately $5.6 million as of March 31, 2024. Reimbursement of these expenditures by our tenants will be determined by each tenant's lease.
The Company expects to fund these expenditures through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.
Notes Receivable
The Company has two notes with a tenant with unfunded commitments remaining totaling $5.1 million at March 31, 2024. See Note 10 – Other Assets, net to the Condensed Consolidated Financial Statements.
Automatic Shelf Registration Statement
On November 2, 2022, the Company filed an automatic shelf registration statement on Form S-3 with the Securities and Exchange Commission. The registration statement is for an indeterminate number of securities and is effective for three years. Under this registration statement, the Company has the capacity to offer and sell from time to time various types of securities, including common stock, preferred stock, depository shares, rights, debt securities, warrants and units.
Operating Activities
Cash flows provided by operating activities for the three months ended March 31, 2024 and 2023 were approximately $12.6 million and $12.7 million, respectively. Cash flows provided by operating activities were generally provided by contractual rents and interest on our notes receivable, net of property operating expenses not reimbursed by the tenants and general and administrative expenses.
Investing Activities
Cash flows used in investing activities for the three months ended March 31, 2024 and 2023 were approximately $38.5 million and $28.6 million, respectively. During the three months ended March 31, 2024, the Company invested in four properties for an aggregate cash consideration of approximately $34.3 million. Also, during the three months ended March 31, 2024, the Company received payments on its notes totaling $0.9 million and funded capital expenditures on its existing portfolio totaling approximately $5.1 million.
During the three months ended March 31, 2023, the Company invested in seven properties for an aggregate cash consideration of approximately $23.9 million and funded notes receivable totaling approximately $1.3 million. Also, during the three months ended March 31, 2023, the Company received payments on its notes receivable totaling $0.8 million and funded capital expenditures on its existing portfolio totaling approximately $4.1 million.
Financing Activities
Cash flows provided by financing activities for the three months ended March 31, 2024 and 2023 were approximately $26.2 million and $8.4 million, respectively. During the three months ended March 31, 2024, the Company (i) borrowed $39.0 million under its Revolving Credit Facility, (ii) completed equity offerings under its at-the-market program, resulting in net proceeds, net of underwriters' discount and offering costs, of approximately $0.5 million, (iii) upon the vesting of stock-based awards for certain employees, withheld shares and paid taxes totaling approximately $0.6 million on behalf of the employees, and (iv) paid dividends totaling approximately $12.7 million.
During the three months ended March 31, 2023, the Company (i) borrowed $12.0 million under its Revolving Credit Facility, (ii) completed equity offerings under its at-the-market program, resulting in net proceeds, net of underwriters' discount and offering costs, of approximately $8.1 million, and (iii) paid dividends totaling approximately $11.6 million.
32

Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Security Deposits
As of March 31, 2024, the Company held approximately $3.7 million in security deposits for the benefit of the Company in the event the obligated tenant fails to perform under the terms of its respective lease. Generally, the Company may, at its discretion and upon notification to the tenant, draw upon the security deposits if there are any defaults under the leases.
Dividends
The Company is required to pay dividends to its stockholders at least equal to 90% of its taxable income in order to maintain its qualification as a REIT.
On April 25, 2024, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.46 per share. The dividend is payable on May 24, 2024 to stockholders of record on May 10, 2024. This rate equates to an annualized dividend of $1.84 per share.
The ability of the Company to pay dividends is dependent upon its ability to generate cash flows and to make accretive new investments.
Corporate Responsibility
The Company is committed to conducting its business according to the highest ethical standards and upholding its corporate responsibilities as a public company operating for the benefit of its stockholders. To that end, the Company modified its Governance Committee to be the Environmental, Social, and Governance (“ESG”) Committee with a revised charter included on the Company’s website at www.chct.reit. Among other duties, the ESG Committee meets at least annually to review and recommend to the Board the general strategy and initiatives regarding ESG matters, including the Company’s internal and external communications and disclosures.
The Company’s Board of Directors has adopted a revised Code of Ethics and Business Conduct that not only applies to its directors, officers, and other employees but also extends the Company's expectations that its vendors, service providers, contractors, and consultants will embrace the Company's commitment to integrity and personal responsibility by complying with this Code at all times. The Code of Ethics and Business Conduct includes the Company’s commitment to promote high standards of integrity by conducting its affairs honestly and ethically and to include in its periodic reports or other publicly available documents information and metrics related to internal monitoring, whistleblower, or reporting systems.
The Company’s whistleblower policy prohibits the Company and its affiliates and their officers, employees and agents from discharging, demoting, suspending, threatening, harassing or in any other manner discriminating against any employee for raising a concern. If an employee desires to raise a concern in a confidential or anonymous manner, the concern may be directed to the whistleblower officer at the Company’s whistleblower hotline. During the quarter ended March 31, 2024, the whistleblower officer received no whistleblower complaints.
The Company’s Information Technology infrastructure is cloud-based, utilizing Software as a Service (“SaaS”) applications for substantially all of its software requirements. Management has formed an IT Committee consisting of the Chief Executive Officer, Chief Financial Officer, and the Vice President of Information Technology to review and discuss information security matters and cyber security risks. The committee meets at least twice a year and reports to the Board of Directors as needed. The Company has adopted the Center of Internet Security (CIS) v8 IG1 cyber security controls including adopting an annual information security training program for its employees. The Company has partnered with a global cyber security leader to continuously and proactively manage and mitigate the ever growing list of cyber threats. As part of the managed monitoring and remediation platform, the Company benefits from a $100,000 breach prevention warranty. Since the Company’s inception, the Company has not had a security breach resulting in expenses, penalties or settlements.
33

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our future income, cash flows and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We may use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We will not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. An interest rate swap is a contractual agreement entered into by two counterparties under which each agrees to make periodic payments to the other for an agreed period of time based on a notional amount of principal. Under the most common form of interest rate swap, known from our perspective as a floating-to-fixed interest rate swap, a series of floating, or variable, rate payments on a notional amount of principal is exchanged for a series of fixed interest rate payments on such notional amount. During the three months ended March 31, 2024, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.
Changes In Internal Control Over Financial Reporting
There were no changes in our system of internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
34

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this Quarterly Report on Form 10-Q, an investor should consider the risk factors included in its Annual Report on Form 10-K for the year ended December 31, 2023 and other reports that may be filed by the Company. There were no material changes in the risk factors presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended March 31, 2024, the Company canceled shares of the Company's common stock to satisfy employee tax withholding obligation payable upon the vesting of stock-based awards, as follows:

Period | Total Number of Shares Purchased | Average Price Paid per share | Total Number of Shares purchased as part of publicly announced plans or programs | Maximum Number of Shares that may yet be purchased under the plans or programs
January 1 - January 31 | 21,261 |  | $ | 25.94 |  | — |  | — |
February 1 - February 29 | — |  | $ | — |  | — |  | — |
March 1 - March 31 | — |  | $ | — |  | — |  | — |
Total | 21,261 |  |  |  |

ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
During the quarter ended March 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
35

ITEM 6. EXHIBITS
The exhibits required by Item 601 of Regulation S-K which are filed with this report are listed in the Exhibit Index and are hereby incorporated in by reference.
EXHIBIT INDEX

Exhibit No. | Description
3.1 | Corporate Charter of Community Healthcare Trust Incorporated, as amended (1)
3.2 | Amended and Restated Bylaws of Community Healthcare Trust Incorporated (2)
10.1 † | Third Amended and Restated Community Healthcare Trust Incorporated Alignment of Interest Program (3)
10.2 † | Third Amended and Restated Community Healthcare Trust Incorporated Executive Officer Incentive Program (4)
10.3 † | Amendment No. 4 to the 2014 Incentive Plan of Community Healthcare Trust Incorporated (5)
10.4 † | Form of Performance-Based Restricted Stock Unit Agreement of Community Healthcare Trust Incorporated (6)
10.5 † | Form of Time-Based Restricted Stock Unit Agreement of Community Healthcare Trust Incorporated (7)
10.6 † | First Amendment to Amended and Restated Employment Agreement between Community Healthcare Trust Incorporated and David H. Dupuy (8)
10.7 † | First Amendment to Employment Agreement between Community Healthcare Trust Incorporated and William G. Monroe (9)
10.8 † | Fifth Amendment to Amended and Restated Employment Agreement between Community Healthcare Trust Incorporated and Leigh Ann Stach (10)
10.9 † | Third Amendment to Employment Agreement between Community Healthcare Trust Incorporated and Timothy L. Meyer (11)
31.1 * | Certification of the Chief Executive Officer of Community Healthcare Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Rule 302 of the Sarbanes-Oxley Act of 2002
31.2 * | Certification of the Chief Financial Officer of Community Healthcare Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Rule 302 of the Sarbanes-Oxley Act of 2002
32.1 ** | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS | Inline XBRL Instance Document
101.SCH | Inline XBRL Taxonomy Extension Schema Document
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

___________________
(1)Filed as Exhibit 3.1 to Amendment No. 2 to the Registration Statement on Form S-11 of the Company filed with the Securities and Exchange Commission on May 6, 2015 (Registration No. 333-203210) and incorporated herein by reference.
(2)Filed as Exhibit 3.2 to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 3, 2020 (File No. 001-37401) and incorporated herein by reference.
(3)Filed as Exhibit 10.1 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 4, 2024 (File No. 001-37401) and incorporated herein by reference.
(4)Filed as Exhibit 10.2 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 4, 2024 (File No. 001-37401) and incorporated herein by reference.
36

(5)Filed as Exhibit 10.3 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 4, 2024 (File No. 001-37401) and incorporated herein by reference.
(6)Filed as Exhibit 10.4 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 4, 2024 (File No. 001-37401) and incorporated herein by reference.
(7)Filed as Exhibit 10.5 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 4, 2024 (File No. 001-37401) and incorporated herein by reference.
(8)Filed as Exhibit 10.1 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 3, 2024 (File No. 001-37401) and incorporated herein by reference.
(9)Filed as Exhibit 10.2 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 3, 2024 (File No. 001-37401) and incorporated herein by reference.
(10)Filed as Exhibit 10.3 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 3, 2024 (File No. 001-37401) and incorporated herein by reference.
(11)Filed as Exhibit 10.4 to the Form 8-K of the Company filed with the Securities and Exchange Commission on January 3, 2024 (File No. 001-37401) and incorporated herein by reference.
* Filed herewith.
** Furnished herewith.
† Denotes executive compensation plan or arrangement.
37

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 30, 2024

| COMMUNITY HEALTHCARE TRUST INCORPORATED
| By: | /s/ David H. Dupuy
|  | David H. Dupuy
|  | Chief Executive Officer and President
| By: | /s/ William G. Monroe IV
|  | William G. Monroe IV
|  | Executive Vice President and Chief Financial Officer

38